Sanofi-a Ventis Deutschland Gmbh

Aventis Pharma Deutschland, Gmbh

Sanofi

Hoescht Aktiengesellschaft

Wendelin Frick

Heiner Glombik

Hubert Heuer

Werner Kramer

Hans-Ludwig Schaefer

Gerhard Jaehne

Andreas Lindenschmidt

Stefanie Flohr

Hans-Ludwig Schäfer

Reinhard Kirsch

Alfons Enhsen

Hans-Ludwig Sch&auml;fer

Stefan Theis

Guenter Mueller

Stefanie Keil

Wolfgang Wendler

Lothar Schwink

Eugen Falk

Oliver Plettenburg

Guenter Billen

Rudolf Schneider

Harm Brummerhop

Werner Krame

Stefan Petry

Matthias Urmann

Bernd Junker

Eric Galia

Hans-Jochen Lang

Klaus Wirth

Uwe Heinelt

Armin Hofmeister

David William Will

Markus Bleich

Heiner Jendralla

Joachim-Heiner Jendralla

Philippe Boffelli

Theodor Andreas Wollmann

Christian Masson

Veronique Crocq

Guy Lemaitre

Francoise Bendetti

Jean-Yves Godard

Theodor Andreas Wollman

David Rigal

Sylvaine Lafont

Jos Hulshof

John Patrick Larkin

Françoise Bendetti

Véronique Crocq

Harm Brummerhof

The invention relates to a method for producing 1,4-benzothiepin-1,1-dioxide derivatives substituted with benzyl groups.

Method for the production of 1,4-benzothiepin-1,1-dioxide derivatives

This invention relates to Novel 1,4-benzothiepin-1,1-dioxide derivatives with improved properties, method for producing the same, drugs containing said compounds and use thereof.

1,4-benzothiepin-1, 1-dioxide derivatives with improved properties method for producing the same, drugs containing said compounds and the use thereof

This invention relates to Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with fluorine, method for producing the same, drugs containing said compounds and use thereof.

1,4-benzothiepin-1,1-dioxide derivatives which are substituted with fluorine, method for producing the same, drugs containing said compounds and use thereof

The present invention relates to a method for identification of a chemical compound which modulates the activity of mammalian GPI-PLC wherein a] a mammalian cell is incubated with glimepiride; b] hcDIGs of the cells of a] are prepared; c] the hcDIGs from b] are incubated with a chemical compound; d] the activity of the GPI-PLC from the hcDIGs of c] is determined.

Glimepiride- and insulin-induced glycosylphosphatidylinositol-specific phospholipase C regulation

This invention relates to Novel 1,4-benzothiepine 1,1-dioxide derivatives substituted by benzyl radicals, method for their preparation, pharmaceuticals comprising these compounds, and the use thereof.

1,4-benzothiepine 1,1-dioxide derivatives substituted by benzyl radicals, method for their preparation, pharmaceuticals comprising these compounds, and the use thereof

This invention relates to Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with cyclohexyl groups, method for producing the same, drugs containing said compounds and use thereof.

1,4-benzothiepin-1,1-dioxide derivatives which are substituted with cyclohexyl groups, method for producing the same, drugs containing said compounds and use thereof

The invention describes a method for isolating an intestinal protein which is able to bind cholesterol and/or cholesterol uptake inhibitors.

Method for isolating an intestinal cholesterol binding protein

The invention relates to the compound of the formula 1 and to its physiologically acceptable salts. The compound is suitable, for example, as a hypolipidemic.

Diphenylazetidinone with improved physiological properties, process for its preparation, medicaments comprising this compound, and its use

Compounds of the formula I, in which R1, R2, R3, R4, R5, and R6 have the meanings given in the description, and their physiologically acceptable salts. The compounds are suitable for use, for example, as hypolipidemics.

Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use

One embodiment of the invention relates to compounds of the formula I, in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification. Other embodiments of the invention relate to physiologically acceptable salts of the compounds of formula I, to processes for their preparation and to medicaments comprising these compounds. The compounds of the invention are suitable for use, for example, as hypolipidemics.

Cationically substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use

Novel thiophene glycoside derivatives of the formula I in which the radicals have the stated meanings, and the physiologically tolerated salts thereof and processes for their preparation are disclosed. The compounds are suitable, for example, as antidiabetics.

Thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof

The invention relates to the compound of the formula (A) and also to its physiologically acceptable salts. The compound is suitable as, for example, a hypolipidemic 

1,4-benzothiazepine 1,1-dioxide derivative, process for its preparation, medicaments comprising this compound, and use thereof as a hypolipidaemic

One embodiment of the invention relates to compounds of the formula I, in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification. Other embodiments of the invention relate to physiologically acceptable salts of compounds of formula I, to processes for their preparation and to medicaments comprising these compounds. The compounds of the invention are suitable for use, for example, as hypolipidemics.

Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds, and their use

The present invention is a process for the preparation of diphenylazetidinone derivatives of the formula (I) or forms thereof comprising the substituents X, Rand/or Ras defined herein. More specifically, the invention comprises methods for the preparation of these compounds by cyclization of certain &#x3b2;-amino carboxamides or &#x3b2;-amino carboxylic esters. These diphenylazetidinone compounds are useful in the treatment of high blood serum cholesterol levels and the maintenance of the reduced cholesterol levels achieved thereby. 

Process for the preparation of diphenyl azetidinone derivatives

Growing community of inventors

Hünstetten-Beuerbach, Germany

Wendelin Frick